000 01248 a2200349 4500
005 20250517181259.0
264 0 _c20180619
008 201806s 0 0 eng d
022 _a1179-1918
024 7 _a10.1007/s40261-017-0583-3
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aKamagata, Eiichiro
245 0 0 _aImprovements in Quality-Adjusted Life Years and Cost-Utility After Pharmacotherapy for Premenstrual Dysphoric Disorder: A Retrospective Study.
_h[electronic resource]
260 _bClinical drug investigation
_cJan 2018
300 _a49-55 p.
_bdigital
500 _aPublication Type: Comparative Study; Journal Article
650 0 4 _aAdolescent
650 0 4 _aAdult
650 0 4 _aCitalopram
_xeconomics
650 0 4 _aCost-Benefit Analysis
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aMiddle Aged
650 0 4 _aPremenstrual Dysphoric Disorder
_xdrug therapy
650 0 4 _aQuality-Adjusted Life Years
650 0 4 _aRetrospective Studies
650 0 4 _aSertraline
_xeconomics
650 0 4 _aYoung Adult
700 1 _aYamada, Kazuo
773 0 _tClinical drug investigation
_gvol. 38
_gno. 1
_gp. 49-55
856 4 0 _uhttps://doi.org/10.1007/s40261-017-0583-3
_zAvailable from publisher's website
999 _c27685195
_d27685195